Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
miR-126 is a microRNA (miRNA) that is highly expressed in endothelial cells and plays a pivotal role in maintaining vascular homeostasis, angiogenesis, and wound healing. In the context of oncology, miR-126 frequently functions as a tumor suppressor, and its expression is often significantly downregulated in various malignancies, including melanoma, breast cancer, and lung cancer. Research indicates that miR-126 modulates the tumor microenvironment by targeting the expression of proteins such as Vascular Cell Adhesion Molecule 1 (VCAM-1), thereby influencing tumor cell adhesion, migration, and invasiveness. Therapeutic strategies involving miR-126 typically focus on the use of miRNA mimics to restore its levels in cancer cells or the vasculature to inhibit tumor progression and improve clinical outcomes.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on miR-126.